Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome

UniQure Biopharma B.V.4 enrolled

Overview

This is an open-label, phase I/II study of intra-cerebral administration of adenovirus-associated viral vector containing the human NAGLU cDNA to children suffering from Sanfilippo type B syndrome.

This is an open-label, phase I/II study of intra-cerebral administration of adenovirus-associated viral vector containing the human NAGLU cDNA to children suffering from Sanfilippo type B syndrome. Four patients, 18 months up to the 5th birthday, have been included. The inclusion period will be 8 to 12 months. The duration of follow-up for each patient is 1 year post-surgery. The duration of the first extension phase is 18 months. The duration of the second extension phase is 36 months. Therefore, the maximum time of the follow-up will be 66 months

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Sanfilippo Syndrome B

Interventions

rAAV2/5-hNAGLUDRUG

one-time brain intraparenchymal gene therapy dose

Eligibility

Sex: ALLMin age: 18 MonthsMax age: 60 Months

Medical Language ↔ Plain English

Inclusion criteria: * Age: 18 months up to 60 months (5th birthday); * Onset of clinical manifestations related to mucopolysaccharidosis type IIIB (MPSIIIB); * NAGLU activity in peripheral blood cell and/or cultured fibroblast extracts of less than 10% of controls; * Patient affiliated to, or covered by a French social security regimen, or European patients with European Health Insurance Card; * Family understanding the procedure and the informed consent; * Signed informed consent by both parents or legal representative; * Vital laboratory parameters within normal range. Exclusion Criteria: * Presence of brain atrophy on baseline MRI judged on a cortico-dural distance of more than 0.6 cm; * Any condition that would contraindicate general anesthesia; * Any other permanent medical condition not related to MPSIIIB that could contraindicate the study participation; * No independent walking (ability to walk without help); * Any medication aiming at modifying the natural course of MPSIIIB given during the 6 months before vector injection (sleep and mood regulators are accepted); * Any condition that would contraindicate treatment with Modigraf®, Cellcept® and prednisolone (Solupred® and Solumedrol®).

Locations (1)

Hopitaux Universitaires Paris-Sud

Paris, Le Kremlin-Bicetre Cedex, France

Outcomes

Primary Outcomes

Number of Participants With Treatment-Related (Serious) Adverse Events as assessed by continuous evaluation of change from baseline

Multiple measurements will be aggregated to derive the number of participants with Abnormal Laboratory Values and/or Adverse Events that are related to Treatment.

Time frame: Baseline until end of study (Month 66)

Secondary Outcomes

Number of Participants with presence of brain atrophy, white matter lesions and other lesions as assessed by cerebral MRI

MRIs at Baseline, Month 3, Month 12, Month 30, Month 48 and last visit Month 66. Cerebral MRI will be collected for safety assessment to retrospectively evaluate for efficacy at Baseline, D0, Month 3, Month12, Month 30 and last visit Month 66.

Time frame: Baseline until end of study (Month 66)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.